RosTrace

Tag: obesity treatment

Robin Hayes

Weight Loss Drugs Linked to Higher Risk of Eye Damage in Diabetic Patients

A large-scale Canadian study has found that use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medicines—widely prescribed to manage diabetes and promote weight loss—may significantly increase the risk of developing neovascular age-related macular degeneration (nAMD) among older diabetic patients. Researchers at the University of Toronto analyzed medical data for more than one million Ontario residents with diabetes and identified a cohort of 46,334 individuals, predominantly taking semaglutide (Ozempic) or, to a lesser extent, lixisenatide. Over a three-year follow-up period, those who used GLP-1 RAs for at least six months exhibited double the risk of new-onset nAMD compared with matched diabetic controls not on these medications. Risk escalated further—to more than three times higher—among patients taking the drugs for 30 months or longer.

· 10 min read

Robin Hayes

FDA Warns Against HCG Weight-Loss Products

The U.S. Food and Drug Administration (FDA) has issued a warning to consumers to avoid using human chorionic gonadotropin (HCG) weight-loss products, which are typically sold in the form of oral drops, pellets, and sprays. These products, often found online, at weight loss clinics, and in some retail stores, are marketed with promises of rapid weight loss and metabolic "resetting" when paired with severely restrictive calorie diets.

· 2 min read

Robin Hayes

New Insights on Obesity Drugs: Uncovering Hidden Health Risks of GLP-1 Medications

This article explores GLP-1 receptor agonists, a class of medications used for type 2 diabetes and weight management. It examines their benefits, including potential cardiovascular improvements and weight loss, while also discussing associated health risks. Recent research highlights the need for diverse study populations to ensure comprehensive understanding of their effects. Future directions in obesity treatment and the importance of informed patient-provider discussions are also addressed, paving the way for personalized approaches in healthcare.

· 5 min read